US: New cholesterol guidelines urge earlier action

High cholesterol, often measured through blood tests, is being addressed with new US guidelines that advocate for earlier intervention. The revised recommendations prioritize identifying and managing unhealthy blood fats to minimize long-term risks of heart attack, stroke, and other cardiovascular issues. An estimated one in four adults in the US has high LDL cholesterol, or "bad" cholesterol, which can lead to plaque buildup in arteries when left elevated over time.

The latest guidelines depart from the 2018 version by shifting focus beyond LDL cholesterol to encompass other lipids and lipoproteins that contribute to dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Cardiologist Roger Blumenthal, who chaired the guideline-writing committee, emphasizes that more than 80 percent of cardiovascular disease is preventable, with elevated LDL cholesterol playing a significant role.

The core message is clear: initiating cholesterol management earlier may provide greater long-term protection. While healthy lifestyle habits are the first step, if lipid levels remain suboptimal despite lifestyle modifications, earlier consideration of lipid-lowering medication could be warranted. Screening for cholesterol should now commence between ages 9 and 11 if a child has not previously been screened, with additional testing possible as early as age 2 for children with a family history of serious cardiovascular or cholesterol-related conditions.

The updated guidelines also incorporate the PREVENT calculator, which estimates an individual's 10-year and 30-year cardiovascular disease risk using data such as cholesterol levels, blood pressure, age, and lifestyle habits. This tool allows for a more personalized assessment of cardiovascular risk based on existing health information obtained during routine physical exams and further personalizes the risk score by factoring in additional risk enhancers.

Specific LDL cholesterol targets have been reintroduced to guide treatment decisions. These goals are less than 100 mg/dL for individuals at borderline or intermediate risk, less than 70 mg/dL for those at high risk, and less than 55 mg/dL for those with established ASCVD who are considered very high risk. Statins remain the primary medication for reducing LDL cholesterol, while alternative options include ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran.

Despite the emphasis on earlier treatment, the new guidelines maintain the importance of healthy lifestyle changes. For those whose cholesterol remains elevated despite adopting healthier habits, doctors may now consider medication sooner, based on the overall cardiovascular risk. The overarching message is that cholesterol management is not solely about reacting to high numbers; regular screening, early action, and maintaining lower harmful cholesterol levels over time can help reduce the risk of heart attack and stroke in the long run.